Human Gene Patents

FacebookSquareVictory

VICTORY! On June 13, 2013, the Supreme Court ruled in our favor to strike down Myriad Genetics’ patents on the human “breast cancer” genes, BRCA1 and BRCA2—and not just Myriad’s patents, but patents on all human genes. This is a tremendous win for women’s health – and for all our health! 

On April 15, 2013 the Supreme Court heard our landmark legal challenge to Myriad Genetics’ patents on the BRCA genes. We rallied at the Supreme Court during oral arguments to take a stand against human gene patents — click here to learn more.

Breast Cancer Action opposes human gene patenting. We believe it’s wrong for the government to give one company the power to dictate all scientific and medical uses of genes that each of us has in our bodies. We urgently need more and better options for the treatment and risk reduction of breast cancer, and we cannot afford to have progress stymied by the monopolies that gene patents create.

In 2009 we took action against gene patenting by joining other women’s health groups, individual women, researchers, genetic counselors, and scientific organizations representing more than 150,000 geneticists, pathologists, and laboratory as a plaintiff in a lawsuit. The lawsuit, filed by the American Civil Liberties Union and the Public Patent Foundation, challenged the legality of the U.S. Patent and Trademark Office’s practice of granting patents on human genes. Specifically, this suit challenges the validity of the patents that grant Myriad Genetics control over the BRCA1 and BRCA2 (the “breast cancer”) genes.

We oppose Myriad Genetics’s patents because the patents gave them exclusive rights to all testing and research on BRCA genes. This monopoly prevents anyone else from so much as examining the genes, and creates barriers to scientific research and medical care relating to breast and ovarian cancer, including:

•    High testing costs.
•    No second opinions.
•    Undermining research.
•    Blocking the development and availability of alternative tests.
•    Lack of data sharing and analysis.
•    Limited information for underserved populations.

Breast Cancer Action is the only national breast cancer organization to join the lawsuit against Myriad Genetics’s patents because we don’t take money from companies that profit from or contribute to cancer. 

For more information: